Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Prospective, Observational Study to Assess the Safety of Sulbactam-durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-calcoaceticus Complex Infection

NCT06746883 is registered in ClinicalTrials.gov with Innoviva Specialty Therapeutics as lead sponsor.

NCT NCT06746883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06746883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Prospective, Observational Study to Assess the Safety of Sulbactam-durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-calcoaceticus Complex Infection
Lead sponsor
Innoviva Specialty Therapeutics
Phase
Observational
Overall status
Recruiting
Start date
April 28, 2025
Completion date
January 31, 2029
Enrollment
100 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acinetobacter baumannii-calcoaceticus complex infection (abc)